WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Computer Hardware Wednesday, February 21, 2018 
Add Press Release News | News Feeds Feeds | Email This News Email


TriNetX Develops Algorithm for Deducing the Chemotherapy Line of Treatment a Patient is Undergoing
Tuesday, February 13, 2018

Unveils Enhanced Real World Data and Analytics for Oncology Clinical Trials

ORLANDO, Fla., Feb. 13, 2018 /PRNewswire/ -- SCOPE Summit -- TriNetX, the global health research network representing nearly 100 million patients, has developed a groundbreaking chemotherapy lines of treatment identification algorithm that understands treatment patterns to deduce the line of chemotherapy treatment a patient is undergoing. This information, up to now nearly impossible to obtain, is critical for biopharmaceutical companies striving to develop therapies for patients involved in care regimens beyond first line treatments.

"Being able to identify which line of chemotherapy treatment corresponds to which subset of a patient's data is truly a breakthrough in oncology data analytics," said Jack London, Informatics Research Professor and Informatics Director, Sidney Kimmel Cancer Center, Thomas Jefferson University. "This type of information is not tracked in traditional EMRs or any other system today. The ability of TriNetX to deliver this data provides huge benefits for both biopharma companies and healthcare organizations in their data driven analyses."

Chemotherapy lines of treatment is the newest component of the industry-leading platform TriNetX has built to help researchers develop effective oncology clinical trial protocols and identify eligible patients. TriNetX is providing access to seamlessly integrated data from EMRs, tumor registries, unstructured pathology reports using natural language processing, and molecular genomics data. The TriNetX platform also predicts how many new patients will become eligible for a clinical trial in the next 12 months on a site by site basis.

"Thousands of clinical trial protocols have been designed with the TriNetX platform," said Matvey Palchuk, VP Informatics, TriNetX. "That experience is combined with an unparalleled understanding of the nuances of real world data, enabling TriNetX to innovate and answer the complex questions inherent to oncology clinical trials."

Network members utilize TriNetX's cloud-based, health research platform to analyze patient populations and perform "what-if" analyses in real-time. As members, healthcare organizations receive hardware and software that are configured within the organization's IT infrastructure and often builds on existing data resources such as i2b2 and Observational Medical Outcomes Partnership (OMOP). Researchers then have access to the institution's de-identified patient data through a user-friendly interface and a growing number of visualization and analysis capabilities.

Biopharmaceutical companies and CROs are presented with aggregate views, but each data point in the TriNetX network can be traced to healthcare organizations who have the ability to identify individual patients. This enables clinical researchers to develop virtual patient cohorts that can then be re-identified for potential recruitment into a clinical trial.

Visit TriNetX in booth #200 at the SCOPE Summit for a live demonstration of the chemotherapy lines of treatment algorithm and additional capabilities for oncology clinical trials.

About TriNetX
TriNetX is the global health research network enabling healthcare organizations, biopharma and contract research organizations (CROs) to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. Each member of our community shares in the consolidated value of our global, federated health research network that connects clinical researchers in real-time to the patient populations which they are attempting to study. For more information, visit TriNetX at https://www.trinetx.com or follow @TriNetX on Twitter.

Media Contacts

Julia Weber
Racepoint Global
(617) 624-3234
trinetx@racepointglobal.com

View original content with multimedia:http://www.prnewswire.com/news-releases/trinetx-develops-algorithm-for-deducing-the-chemotherapy-line-of-treatment-a-patient-is-undergoing-300597436.html

SOURCE TriNetX



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav Simplitfy Named Among "Best Entrepreneurial Companies in America" by Entrepreneur Magazine's 2017 Entrepreneur360 List | Feb 21, 2018
Nav Global 3D IC & 2.5D IC Packaging Market 2015-2017 & 2018-2027 - Increasing Demand for High-End Computing, Servers, and Data Centers | Feb 21, 2018
Nav Cymer qualifies and ships new argon fluoride light source | Feb 21, 2018
Nav Vestarin Project Presents Screenshots of its Desktop Application for the First Time | Feb 21, 2018
Nav Glassdoor Appoints James Cox As Chief Financial Officer | Feb 21, 2018
Nav Semiconductor Stocks' Research Reports Released on Entegris, Kulicke and Soffa Industries, Universal Display, and Veeco Instruments | Feb 21, 2018
Nav Global Web Application Firewall Market Analysis & Trends Report 2018-2027 | Feb 21, 2018
Nav FutureDial Announces Strategic Partnership with OptoFidelity | Feb 21, 2018
Nav RADCOM Collaborates With Red Hat to Accelerate Operators' Transition to Cloud-Native Assurance | Feb 21, 2018
Nav ESO Releases New Properties and Inspections Software for Fire Departments | Feb 21, 2018
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News